IMPROVED TRIPLE HELIX FORMING OLIGONUCLEOTIDES

Information

  • Research Project
  • 3489714
  • ApplicationId
    3489714
  • Core Project Number
    R43AI033761
  • Full Project Number
    1R43AI033761-01
  • Serial Number
    33761
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1992 - 31 years ago
  • Project End Date
    3/31/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1992 - 31 years ago
  • Budget End Date
    3/31/1993 - 31 years ago
  • Fiscal Year
    1992
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/30/1992 - 31 years ago

IMPROVED TRIPLE HELIX FORMING OLIGONUCLEOTIDES

DESCRIPTION (Adapted from applicant's abstract): Triple helix forming oligonucleotides (TFOs) offer the potential to specifically modulate expression of any gene in a sequence dependent manner. At present, TFOs can be designed to bind to certain targets in duplex DNA, forming a localized three-stranded structure. Such structures can block action of a variety of DNA binding proteins, including transcription factors. TFOs can be administered in cell culture and are taken up and transported to the cell nucleus. Thus, intervention in the expression of specific genes relevant to various disease states may soon be practical. TFOs consisting of guanosine and thymidine residues that bind to duplex DNA, forming a series of GGC and TAT base triplets, are being studied. Recently, indications are that T is relatively nonspecific in that it binds with similar affinity to AT, GC, and CG base pairs. This may significantly reduce the specificity of a given TFO, leading to undesired effects on the expression of genes unrelated to the intended target. Preliminary studies indicate the base analog pyrido-pyrimidine affords comparable binding affinity and significantly greater specificity for AT base pairs. Additional experiments designed to confirm these results and extend them to antiviral studies in culture are proposed.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    TRIPLEX PHARMACEUTICAL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    THE WOODLANDS
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    77380
  • Organization District
    UNITED STATES